Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Get Free Report) CEO James F. Oliviero III sold 24,610 shares of the business’s stock in a transaction that occurred on Wednesday, June 26th. The shares were sold at an average price of $2.05, for a total transaction of $50,450.50. Following the sale, the chief executive officer now owns 1,977,170 shares of the company’s stock, valued at $4,053,198.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Checkpoint Therapeutics Price Performance
Shares of NASDAQ:CKPT traded up $0.09 during mid-day trading on Friday, reaching $2.15. 252,621 shares of the company traded hands, compared to its average volume of 477,131. The company’s 50 day moving average price is $1.78 and its 200-day moving average price is $1.93. The firm has a market cap of $76.73 million, a PE ratio of -0.78 and a beta of 1.13. Checkpoint Therapeutics, Inc. has a 52 week low of $1.30 and a 52 week high of $3.62.
Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report) last released its earnings results on Friday, May 10th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.04. On average, research analysts predict that Checkpoint Therapeutics, Inc. will post -1.29 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Checkpoint Therapeutics
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a “buy” rating and set a $34.00 price target on shares of Checkpoint Therapeutics in a research note on Monday. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Checkpoint Therapeutics has an average rating of “Buy” and a consensus price target of $22.60.
Get Our Latest Stock Analysis on CKPT
Checkpoint Therapeutics Company Profile
Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.
Read More
- Five stocks we like better than Checkpoint Therapeutics
- CD Calculator: Certificate of Deposit Calculator
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- Want to Profit on the Downtrend? Downtrends, Explained.
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.